[1] Ahmad J, Odin JA. Epidemiology and genetic risk factors of drug hepatotoxicity. Clin Liver Dis, 2017; 21, 55−72. doi:  10.1016/j.cld.2016.08.004
[2] Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis, 2014; 34, 115−22. doi:  10.1055/s-0034-1375953
[3] Zhang YM, Sun WJ, Wen LZ, et al. Clinical features of patients with drug-induced liver injury in China in the last five years. J Clin Hepatol, 2018; 34, 562−6. (In Chinese
[4] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014; 109, 950−66. doi:  10.1038/ajg.2014.131
[5] Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the food and drug administration, 1998-2005. Arch Intern Med, 2007; 167, 1752−9. doi:  10.1001/archinte.167.16.1752
[6] Guy J, Peters MG. Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol Hepatol (N Y), 2013; 9, 633−9.
[7] Zimmermann HW, Trautwein C, Tacke F. Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front Physiol, 2012; 3, 56.
[8] Wu ZG, Han MF, Chen T, et al. Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int, 2010; 30, 782−94. doi:  10.1111/j.1478-3231.2010.02262.x
[9] European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol, 2019; 70, 1222−61. doi:  10.1016/j.jhep.2019.02.014
[10] Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. , 2016; 36, 158-65.
[11] Dara L, Liu ZX, Kaplowitz N. Pathogenesis of idiosyncratic drug induced liver injury. In: Muriel P. Liver Pathophysiology. Elsevier. 2017, 87-100.
[12] Tailor A, Faulkner L, Naisbitt DJ, et al. The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury. Hum Exp Toxicol, 2015; 34, 1310−7. doi:  10.1177/0960327115606529
[13] Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol, 2011; 8, 202−11. doi:  10.1038/nrgastro.2011.22
[14] Adams DH, Ju C, Ramaiah SK, et al. Mechanisms of immune-mediated liver injury. Toxicol Sci, 2010; 115, 307−21. doi:  10.1093/toxsci/kfq009
[15] Wang XZ, Zhang LY, Jiang ZZ. T‐helper cell‐mediated factors in drug-induced liver injury. J Appl Toxicol, 2015; 35, 695−700. doi:  10.1002/jat.3115
[16] Jin B, Sun T, Yu XH, et al. The effects of TLR activation on T-cell development and differentiation. J Immunol Res, 2012; 2012, 836485.
[17] Wang XZ, Jiang ZZ, Cao WP, et al. Th17/Treg imbalance in triptolide-induced liver injury. Fitoterapia, 2014; 93, 245−51. doi:  10.1016/j.fitote.2014.01.006
[18] Laverty HG, Antoine DJ, Benson C, et al. The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol, 2010; 66, 961−76. doi:  10.1007/s00228-010-0862-x
[19] Eisenberg-Lerner A, Kimchi A. PKD is a kinase of Vps34 that mediates ROS- induced autophagy downstream of DAPk. Cell Death Differ, 2012; 19, 788−97. doi:  10.1038/cdd.2011.149
[20] Ding WX, Manley S, Ni HM. The emerging role of autophagy in alcoholic liver disease. Exp Biol Med (Maywood), 2011; 236, 546−56. doi:  10.1258/ebm.2011.010360
[21] Roth RA, Ganey PE. Role of inflammation in drug-induced liver injury. In: Kaplowitz N, Deleve LD. Drug-Induced Liver Disease. Academic Press. 2013, 157-73.
[22] Relja B, Land WG. Damage-associated molecular patterns in trauma. Eur J Trauma Emerg Surg, 2020; 46, 751−75. doi:  10.1007/s00068-019-01235-w
[23] Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci, 2019; 20, 6008. doi:  10.3390/ijms20236008
[24] Josephs SF, Ichim TE, Prince SM, et al. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. J Transl Med, 2018; 16, 242. doi:  10.1186/s12967-018-1611-7
[25] Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol, 2018; 10, a028415. doi:  10.1101/cshperspect.a028415
[26] Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol, 2018; 18, 773−89. doi:  10.1038/s41577-018-0066-7
[27] Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol, 2015; 16, 448−57. doi:  10.1038/ni.3153
[28] Guo G, Zhu YJ, Wu ZR, et al. Circulating monocytes accelerate acute liver failure by IL-6 secretion in monkey. J Cell Mol Med, 2018; 22, 4056−67. doi:  10.1111/jcmm.13673
[29] Kong LX, Zhou YJ, Bu H, et al. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice. J Exp Clin Cancer Res, 2016; 35, 131. doi:  10.1186/s13046-016-0412-1
[30] Shao MY, Xu Q, Wu ZR, et al. Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p. Stem Cell Res Ther, 2020; 11, 37. doi:  10.1186/s13287-020-1550-0